Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Summary

A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.

Timeline

Start

2011-03

Primary completion

2017-09-26

Completion

2017-10-31

Publications

• Staehler M, Stockle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Bruning F, Goebell PJ, Augustin M, Roos F, Benz-Rud I, Marschner N, Grunwald V. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer. 2021 Apr 1;148(7):1685-1694. doi: 10.1002/ijc.33349. Epub 2020 Oct 26.

Drugs

Indications